Literature DB >> 18507015

Prediction of tumour regrowth of pontine glioma using a two-term model.

Ming Zhang1, Florian Segerer, Leena Ketonen, Anita Mahajan, Johannes Wolff.   

Abstract

BACKGROUND: Modelling tumour regrowth kinetics and determining tumour burden is critically important in making accurate patient prognoses. PATIENTS AND METHODS: Our two-term model, which describes tumour regrowth after chemotherapy was tested by analyzing tumour sizes in patients with pontine gliomas treated at a major cancer centre during the past 40 years. Tumour measurements at four early time points were used to fit the model, which was then used to predict later tumour sizes. The predictions were compared with observed measurements from clinical charts and this model's performance was compared to that of a quadratic model.
RESULTS: The mean of relative errors using the two-term model was 0.186; standard deviation, 0.176. For the quadratic model, the mean of relative errors was 0.412; standard deviation, 0.521.
CONCLUSION: The two-term model fits the tumour regrowth data reasonably well and is more accurate than a competing quadratic model used in the same way (p < 0.05).

Entities:  

Mesh:

Year:  2008        PMID: 18507015

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.

Authors:  Yue Wei; Tapan Kadia; Weigang Tong; Ming Zhang; Yu Jia; Hui Yang; Yumin Hu; Francesco Paolo Tambaro; Jean Viallet; Susan O'Brien; Guillermo Garcia-Manero
Journal:  Clin Cancer Res       Date:  2010-06-10       Impact factor: 12.531

2.  High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study.

Authors:  Johannes E Wolff; Rolf-Dieter Kortmann; Birte Wolff; Torsten Pietsch; Ove Peters; Hans-Joerg Schmid; Stefan Rutkowski; Monika Warmuth-Metz; Christoph Kramm
Journal:  J Neurooncol       Date:  2010-08-08       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.